Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01467492 · ClinicalTrials.gov registry record · Phase 4
Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C
A Phase 4 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Terminated
- Registry status
- Phase 4
- Development phase
- 121
- Enrollment target
NCT01467492 is a Phase 4 study that was terminated before completion, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 121 participants.
The verdict
NCT01467492, a Phase 4 study, was terminated before completion, sponsored by Vertex Pharmaceuticals Incorporated.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 121 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of telaprevir in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) and ribavirin (RBV) in treatment-experienced Black/African American and non-Black/African American participants with Genotype 1 Chronic Hepatitis C (CHC), who have not achieved a sustained viral response with a prior course of interferon-based therapy.
Interventions
- DRUG Ribavirin
- DRUG Telaprevir
- BIOLOGICAL Pegylated Interferon Alfa-2a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2012-01 |
| Est. Completion | 2014-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01467492
The ClinicalTrials.gov registry entry for NCT01467492 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ribavirin is the first listed.
NCT01467492 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01467492 about?
NCT01467492 is a clinical study titled "Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C". The purpose of this study is to evaluate the efficacy and safety of telaprevir in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) and ribavirin (RBV) in treatment-experienced Black/African American and non-Black/African American participants with Genotype 1 Chronic Hepatitis C (CHC),...
What is the current status of trial NCT01467492?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 121 participants. The study started on 2012-01. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01467492?
The interventions under investigation include: Ribavirin (DRUG), Telaprevir (DRUG), Pegylated Interferon Alfa-2a (BIOLOGICAL).
Who is sponsoring clinical trial NCT01467492?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.